vs
Andersons, Inc.（ANDE）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Andersons, Inc.的1.9倍（$622.0M vs $329.5M），Royalty Pharma plc净利率更高（34.4% vs 20.5%，领先14.0%），Royalty Pharma plc同比增速更快（4.8% vs -2.4%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -1.8%）
安德森公司（The Andersons, Inc.）是1947年成立的美国农业企业，总部位于俄亥俄州莫米。公司起源于1940年代服务粮食行业的安德森货运站，是深耕农业领域的多元化企业，业务覆盖大宗商品贸易、可再生能源以及植物营养板块。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ANDE vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.9倍
$329.5M
营收增速更快
RPRX
高出7.1%
-2.4%
净利率更高
RPRX
高出14.0%
20.5%
两年增速更快
RPRX
近两年复合增速
-1.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $329.5M | $622.0M |
| 净利润 | $67.4M | $214.2M |
| 毛利率 | 70.3% | — |
| 营业利润率 | 26.6% | 62.4% |
| 净利率 | 20.5% | 34.4% |
| 营收同比 | -2.4% | 4.8% |
| 净利润同比 | 49.6% | 2.9% |
| 每股收益（稀释后） | — | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANDERPRX
| Q4 25 | $329.5M | $622.0M | ||
| Q3 25 | $295.8M | $609.3M | ||
| Q2 25 | $535.0M | $578.7M | ||
| Q1 25 | $370.8M | $568.2M | ||
| Q4 24 | $337.5M | $593.6M | ||
| Q3 24 | $231.9M | $564.7M | ||
| Q2 24 | $492.5M | $537.3M | ||
| Q1 24 | $341.4M | $568.0M |
净利润ANDERPRX
| Q4 25 | $67.4M | $214.2M | ||
| Q3 25 | $20.1M | $288.2M | ||
| Q2 25 | $7.9M | $30.2M | ||
| Q1 25 | $284.0K | $238.3M | ||
| Q4 24 | $45.1M | $208.2M | ||
| Q3 24 | $27.4M | $544.0M | ||
| Q2 24 | $36.0M | $102.0M | ||
| Q1 24 | $5.6M | $4.8M |
毛利率ANDERPRX
| Q4 25 | 70.3% | — | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 29.6% | — | ||
| Q1 25 | 41.2% | — | ||
| Q4 24 | 63.1% | — | ||
| Q3 24 | 76.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 37.6% | — |
营业利润率ANDERPRX
| Q4 25 | 26.6% | 62.4% | ||
| Q3 25 | 8.7% | 70.1% | ||
| Q2 25 | 4.6% | 36.3% | ||
| Q1 25 | 0.9% | 94.0% | ||
| Q4 24 | 19.9% | 60.9% | ||
| Q3 24 | 26.8% | — | ||
| Q2 24 | 11.6% | 50.2% | ||
| Q1 24 | 4.1% | -13.0% |
净利率ANDERPRX
| Q4 25 | 20.5% | 34.4% | ||
| Q3 25 | 6.8% | 47.3% | ||
| Q2 25 | 1.5% | 5.2% | ||
| Q1 25 | 0.1% | 41.9% | ||
| Q4 24 | 13.4% | 35.1% | ||
| Q3 24 | 11.8% | 96.3% | ||
| Q2 24 | 7.3% | 19.0% | ||
| Q1 24 | 1.6% | 0.8% |
每股收益（稀释后）ANDERPRX
| Q4 25 | — | $0.49 | ||
| Q3 25 | $0.59 | $0.67 | ||
| Q2 25 | $0.23 | $0.07 | ||
| Q1 25 | $0.01 | $0.55 | ||
| Q4 24 | $1.31 | $0.46 | ||
| Q3 24 | $0.80 | $1.21 | ||
| Q2 24 | $1.05 | $0.23 | ||
| Q1 24 | $0.16 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.3M | $618.7M |
| 总债务越低越好 | $560.0M | $9.0B |
| 股东权益账面价值 | $1.2B | $9.7B |
| 总资产 | $3.7B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.45× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ANDERPRX
| Q4 25 | $98.3M | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $561.8M | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务ANDERPRX
| Q4 25 | $560.0M | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $608.2M | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益ANDERPRX
| Q4 25 | $1.2B | $9.7B | ||
| Q3 25 | $1.2B | $9.6B | ||
| Q2 25 | $1.4B | $9.5B | ||
| Q1 25 | $1.4B | $9.8B | ||
| Q4 24 | $1.4B | $10.3B | ||
| Q3 24 | $1.3B | $10.3B | ||
| Q2 24 | $1.3B | $9.8B | ||
| Q1 24 | $1.3B | $9.9B |
总资产ANDERPRX
| Q4 25 | $3.7B | $19.6B | ||
| Q3 25 | $3.3B | $19.3B | ||
| Q2 25 | $3.4B | $18.3B | ||
| Q1 25 | $3.8B | $17.6B | ||
| Q4 24 | $4.1B | $18.2B | ||
| Q3 24 | $3.4B | $18.0B | ||
| Q2 24 | $3.3B | $17.7B | ||
| Q1 24 | $3.3B | $16.1B |
负债/权益比ANDERPRX
| Q4 25 | 0.45× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.45× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.2M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-77.1M | — |
| 自由现金流率自由现金流/营收 | -23.4% | — |
| 资本支出强度资本支出/营收 | 21.5% | — |
| 现金转化率经营现金流/净利润 | -0.09× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $-56.1M | — |
8季度趋势，按日历期对齐
经营现金流ANDERPRX
| Q4 25 | $-6.2M | $827.1M | ||
| Q3 25 | $233.9M | $702.6M | ||
| Q2 25 | $299.3M | $364.0M | ||
| Q1 25 | $-350.0M | $596.1M | ||
| Q4 24 | $268.8M | $742.5M | ||
| Q3 24 | $-2.1M | $703.6M | ||
| Q2 24 | $304.4M | $658.2M | ||
| Q1 24 | $-239.6M | $664.6M |
自由现金流ANDERPRX
| Q4 25 | $-77.1M | — | ||
| Q3 25 | $167.0M | — | ||
| Q2 25 | $250.5M | — | ||
| Q1 25 | $-396.6M | — | ||
| Q4 24 | $212.9M | — | ||
| Q3 24 | $-40.0M | — | ||
| Q2 24 | $275.8M | — | ||
| Q1 24 | $-266.4M | — |
自由现金流率ANDERPRX
| Q4 25 | -23.4% | — | ||
| Q3 25 | 56.5% | — | ||
| Q2 25 | 46.8% | — | ||
| Q1 25 | -106.9% | — | ||
| Q4 24 | 63.1% | — | ||
| Q3 24 | -17.2% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | -78.0% | — |
资本支出强度ANDERPRX
| Q4 25 | 21.5% | — | ||
| Q3 25 | 22.6% | — | ||
| Q2 25 | 9.1% | — | ||
| Q1 25 | 12.6% | — | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 16.3% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | 7.8% | — |
现金转化率ANDERPRX
| Q4 25 | -0.09× | 3.86× | ||
| Q3 25 | 11.61× | 2.44× | ||
| Q2 25 | 38.10× | 12.06× | ||
| Q1 25 | -1232.46× | 2.50× | ||
| Q4 24 | 5.96× | 3.57× | ||
| Q3 24 | -0.08× | 1.29× | ||
| Q2 24 | 8.46× | 6.45× | ||
| Q1 24 | -42.94× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
